Relmada Therapeutics Inc
Change company Symbol lookup
Select an option...
RLMD Relmada Therapeutics Inc
LMND Lemonade Inc
NAACW North Atlantic Acquisition Equity Warrant Exp 20 Oct 2025 *W EXP 10/20/2025
CG Carlyle Group Inc
ETR Entergy Corp
SKIN Beauty Health Co
PYR Pyrogenesis Canada Inc
KHZM Madison Ave Media Inc
PEO Adams Natural Resources Fund
MF Missfresh Ltd
Go

Health Care : Pharmaceuticals | Small Cap Growth
Company profile

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), which is an N-methyl-D-aspartate (NMDA) receptor antagonist. The Company’s lead product candidate, esmethadone, is a new chemical entity (NCE) developed as a rapidly acting, oral agent for the treatment of depression, central nervous system (CNS) diseases and other potential indications. The Company’s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission and is in development for both the adjunctive or monotherapy treatment of major depressive disorder (MDD).

Closing Price
$33.23
Day's Change
1.45 (4.56%)
Bid
--
Ask
--
B/A Size
--
Day's High
33.44
Day's Low
31.50
Volume
(Light)
Volume:
381,525

10-day average volume:
571,687
381,525

Jushi settles lawsuit over ex-CFO who just joined Curaleaf

8:39 am ET August 8, 2022 (MarketWatch)
Print

Jushi Holdings Inc. said Monday it settled a lawsuit with Curaleaf Holdings Inc. and with its former CFO Edward Kremer. Curaleaf on Monday named Kremer as its new CFO. Curaleaf also named Camilo Lyon as chief investment officer and Mitch Hara as chief strategy officer, which is a new role at the cannabis company. Filed on July 15, the Jushi lawsuit alleged breach of Kremer's employment agreement. The suit also lodged a complaint against Curaleaf for "tortious interference." The cannabis company said Kremer has agreed to abide by his other continuing obligations to the company in exchange for a limited waiver of his non-compete to allow him to accept employment with Curaleaf. Curaleaf has also committed to strengthen the commercial relationship between Jushi and Curaleaf, the company said. Shares of Jushi are down about 37% in 2022 compared to a loss of 54% by the AdvisorShares Pure U.S. Cannabis ETF (MSOS) and a drop of 19.1% by the Nasdaq . Curaleaf shares are down 38% in 2022.

-Steve Gelsi

	

(END) Dow Jones Newswires

August 08, 2022 08:39 ET (12:39 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.